Cevimeline Ophthalmic Solution - BioThera Vision
Alternative Names: BVT-100Latest Information Update: 03 Mar 2025
At a glance
- Originator Unknown
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Dry eyes
Most Recent Events
- 31 Dec 2024 Phase-II clinical trials in Dry eyes in Australia, Taiwan (Ophthalmic) (NCT06543303)